Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04321954 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
A Phase 2 study of Advanced Cancer and Differentiated Thyroid Cancer, sponsored by Massachusetts Eye and Ear Infirmary.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT04321954: Active Phase 2 study of Advanced Cancer and Differentiated Thyroid Cancer, sponsored by Massachusetts Eye and Ear Infirmary.
NCT04321954 is a Phase 2 study of Advanced Cancer and Differentiated Thyroid Cancer that is active but no longer recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 30 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04321954, a Phase 2 study of Advanced Cancer and Differentiated Thyroid Cancer, is active but no longer recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Primary Outcome
Evaluate the overall R0/R1 resection rate, as defined by proportion of patients who undergo successful thyroidectomy with clear (R0) or microscopically positive surgical margins (R1).
Conditions Studied
Interventions
- DRUG LENVATINIB
Study Locations (3)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2026-05-27 |
| Phase | Phase 2 |
What the registry record for NCT04321954 still lists
NCT04321954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which LENVATINIB is the first listed.
NCT04321954 reports a single indexed study location in Massachusetts, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04321954 about?
NCT04321954 is a clinical study titled "Lenvatinib in Locally Advanced Invasive Thyroid Cancer". This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
What is the current status of trial NCT04321954?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-03-09. Estimated completion is 2026-05-27.
What conditions does trial NCT04321954 study?
This clinical trial studies the following conditions: Advanced Cancer, Differentiated Thyroid Cancer.
What interventions are being tested in trial NCT04321954?
The interventions under investigation include: LENVATINIB (DRUG).
Who is sponsoring clinical trial NCT04321954?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04321954 being conducted?
This trial has 3 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04321954's enrollment target sits among peer trials
30 97th of 122 higher than 20 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI